Search | Clinical Trials Finder

Conditions: Atopic Dermatitis, Pruritus
Interventions: RD047-26; Device
Lead sponsor: Oculus Innovative Sciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Ankylosing Spondylitis
Interventions: AIN457A; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more

Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Healthy
Interventions: Atorvastatin, Metformin, Ulonivirine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Duchenne Muscular Dystrophy
Interventions: Viltolarsen; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 8 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 26
States / cities: Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more

Conditions: Ovarian Cancer
Interventions: SGI-110, Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine), Carboplatin; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 13
States / cities: Los Angeles, California • Gainesville, Florida • Augusta, Georgia + 10 more

Conditions: Multiple Myeloma
Interventions: P-BCMA-101 CAR-T cells, Rimiducid; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Gilbert, Arizona • Davis, California • San Diego, California + 11 more

Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions: Allogeneic NK Cells; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Tuberous Sclerosis Complex
Interventions: everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo Matched to Alirocumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 11
States / cities: Mission Viejo, California • Newport Beach, California • Thousand Oaks, California + 8 more

Conditions: Fabry Disease
Interventions: Agalsidase alfa; Drug
Lead sponsor: Shire; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 13
States / cities: Tucson, Arizona • Palm Beach Gardens, Florida • Lake Charles, Louisiana + 9 more

Conditions: Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder, Safety Issues
Interventions: E-CEL UVEC; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 45 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoglycemia, Diabetes Mellitus
Interventions: Nasal Glucagon; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Tallahassee, Florida • Baltimore, Maryland • Waltham, Massachusetts

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Interventions: Not listed
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 6
States / cities: Lomita, California • Clearewater, Florida • Fleming Island, Florida + 3 more

Conditions: Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
Interventions: AVA6000; Drug
Lead sponsor: Avacta Life Sciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: New York, New York • Houston, Texas • Seattle, Washington

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Congenital Cytomegaloviral (CMV) Disease
Interventions: CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy; Biological · Drug
Lead sponsor: New York Medical College; Other
Eligibility: 0 Days to 21 Days
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • St Louis, Missouri • Vallhala, New York + 1 more

Conditions: Breast Neoplasms
Interventions: Imlunestrant, Goserelin, Tamoxifen 20 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 34
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more

Conditions: Friedreich Ataxia
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Up to 6 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer
Interventions: PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tustin, California

Conditions: Pharmacology, Clinical
Interventions: Aspirin (Acetylsalicylic acid, BAYe4465); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Hackensack, New Jersey

Search by objective public record fields.

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

SGI-110 in Combination With Carboplatin in Ovarian Cancer

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Replagal Enzyme Replacement Therapy for Children With Fabry Disease

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

CMV CTLs in Neonates With CMV Infection

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.